Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 36 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 InsertionCompletedNCT05419700
• Developing a Shared Decision Making Tool for Patients With Surgically Removed Non-small Cell Lung CancerCompletedNCT05416983
• Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer PatientsActive, not recruitingNCT05415358
• Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and LungWithdrawnNCT05412875Not applicable
• A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2Status unknownNCT05411276
• Remote Monitoring with Health-Coaching for Lifestyle Changes in Patients with Lung Cancer Related FatigueTerminatedNCT05407038Not applicable
• Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung CancerActive, not recruitingNCT05403385Phase 2
• Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLCActive, not recruitingNCT05401786Phase 2
• Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLCWithdrawnNCT05400577Phase 2
• ITIL-306 in Advanced Solid TumorsTerminatedNCT05397093Phase 1
• Exhaled Breath Particles in Lung CancerStatus unknownNCT05395611
• ITIL-168 in Advanced Solid TumorsWithdrawnNCT05393635Phase 1
• Real-world Association Between Concomitant Beta-blocker Exposure and Anti-PD-1/PD-L1 Treatment Outcomes in Advanced Non-Small Cell Lung CancerCompletedNCT05387512
• Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung CancerStatus unknownNCT05387109Phase 4
• SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint InhibitorsStatus unknownNCT05387044Phase 2
• A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLCCompletedNCT05386888Phase 2
• Neoadjuvant/Adjuvant Pembrolizumab Plus ChemotherapyActive, not recruitingNCT05383716Phase 2
• Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)WithdrawnNCT05383001Phase 2
• Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant TreatmentActive, not recruitingNCT05382052
• Brain Metabolic Network of PET in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT05380908
• A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung CancerStatus unknownNCT05380024Phase 2
• Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung CancerStatus unknownNCT05377788
• Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC PatientsCompletedNCT05375994Phase 1/2
• SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS MutationTerminatedNCT05375084Phase 1
• Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung CancerCompletedNCT05372081
• Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung CancerWithdrawnNCT05364645Phase 2
• Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsActive, not recruitingNCT05364073Phase 1
• A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.Status unknownNCT05361564Phase 2
• HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05360381Phase 1
• Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR KitCompletedNCT05360225
• Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationTerminatedNCT05358249Phase 1/2
• A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.Active, not recruitingNCT05355701Phase 1
• A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128Active, not recruitingNCT05354102Phase 1
• Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung CancerCompletedNCT05348668Phase 2
• Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR KitCompletedNCT05348187Not applicable
• Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR KitCompletedNCT05347797Not applicable
• Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT05347628Phase 1
• A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).Status unknownNCT05346952Phase 3
• Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung CancerActive, not recruitingNCT05340309Phase 2
• Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint InhibitorsActive, not recruitingNCT05334329Phase 1
• Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.CompletedNCT05331833
• A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid TumorsStatus unknownNCT05329298Phase 1/2
• A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung CancerActive, not recruitingNCT05329025Phase 2
• Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)CompletedNCT05321212
• SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung CancerActive, not recruitingNCT05319574Phase 2
• A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung CancerCompletedNCT05318443Phase 3
• Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI TherapyStatus unknownNCT05314296
• Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung CancerCompletedNCT05312840Phase 2
• Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung CancerCompletedNCT05304793Not applicable
• Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and MelanomaCompletedNCT05303493Phase 1
• Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRITerminatedNCT05302817Phase 1
• Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)CompletedNCT05298423Phase 3
• Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC TumorsCompletedNCT05298176Phase 2
• Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRsCompletedNCT05292859
• Stereotactic Ablative Radiotherapy in Locally Advanced Non Small Cell Lung CancerCompletedNCT05291780Not applicable
• Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural EffusionStatus unknownNCT05291403Not applicable
• Standard of Care Lifestyle Support for Stage III NSCLC PatientsWithdrawnNCT05287971
• A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard TherapyStatus unknownNCT05287386Phase 2
• Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical RespondersActive, not recruitingNCT05286294Phase 2
• TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung CancerStatus unknownNCT05284994Phase 1/2
• Lazertinib for Patients With NSCLC Harboring Uncommon EGFR MutationsStatus unknownNCT05277701Phase 2
• First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingNCT05277051Phase 1
• Study of MGY825 in Patients With Advanced Non-small Cell Lung CancerTerminatedNCT05275868Phase 1
• A Study to Investigate LYL797 in Adults With Solid TumorsTerminatedNCT05274451Phase 1
• Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung CancerStatus unknownNCT05273814Phase 1
• Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung CancerCompletedNCT05269485Phase 2
• Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or ChemoradiotherapyStatus unknownNCT05267392Phase 1/2
• Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLCStatus unknownNCT05265650Phase 1/2
• Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R MutationCompletedNCT05263947Phase 2
• Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCCompletedNCT05261438
• Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung CancerStatus unknownNCT05257512Phase 1/2
• Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsActive, not recruitingNCT05256290Phase 1/2
• Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)Status unknownNCT05255406Phase 2
• Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual CareActive, not recruitingNCT05254795Not applicable
• DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTSActive, not recruitingNCT05254119
• An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLCStatus unknownNCT05252091Phase 2
• Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung CancerStatus unknownNCT05252065
• A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung CancerCompletedNCT05250817
• Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLCActive, not recruitingNCT05244213Phase 2
• Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLCStatus unknownNCT05243355Phase 2
• (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsTerminatedNCT05241873Phase 1
• A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to TreatmentCompletedNCT05241834Phase 1
• A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).Active, not recruitingNCT05240131Phase 1/2
• P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05239143Phase 1
• A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid TumorsActive, not recruitingNCT05238883Phase 1
• Pulmonary Magnetic Resonance-guided Online Adaptive Radiotherapy of Locally Advanced Non-Small Cell Lung CancerActive, not recruitingNCT05237453Not applicable
• A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLCStatus unknownNCT05236608Phase 1/2
• A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid TumorsWithdrawnNCT05234606Phase 1/2
• PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid TumorsTerminatedNCT05233436Phase 1
• Comprehensive Geriatric Assessment in Elderly Non-Small Cell Lung Cancer PatientsWithdrawnNCT05230888
• A Study of SGN-ALPV in Advanced Solid TumorsTerminatedNCT05229900Phase 1
• Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung CancerCompletedNCT05226728Phase 1
• Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET InhibitorNo longer availableNCT05225259
• A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLCStatus unknownNCT05223595Phase 1
• A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerActive, not recruitingNCT05221840Phase 3
• Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT05215340Phase 3
• A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCCWithdrawnNCT05212922Phase 2
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCActive, not recruitingNCT05211895Phase 3
• A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer PatientsStatus unknownNCT05210946Not applicable
• THIO Sequenced With Cemiplimab in Advanced NSCLCActive, not recruitingNCT05208944Phase 2

← Carcinoma, Non-Small-Cell Lung overview